Jérôme Alexandre

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im et al. · The Lancet Oncology · 2020 · 435 citations

Phase 1/2, Breast Oncology, Oncology +8

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

Alejandro Yovine, M. Riofrio, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 2004 · 309 citations

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial

Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto et al. · Journal of Clinical Oncology · 2016 · 139 citations

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

David M. O’Malley, Ana Oaknin, Bradley J. Monk et al. · Gynecologic Oncology · 2021 · 127 citations · Full text

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

Patricia Pautier, Anne Floquet, Christine Chevreau et al. · The Lancet Oncology · 2015 · 112 citations

Gynecological Surgery, Medicine, Gynecology +6